Inquiries from Congress pose unique risks to a company’s legal, business and reputational standing, and often take place against the backdrop of parallel executive branch and other governmental inquiries. In this high-stakes environment, our bipartisan congressional investigations team provides grounded, strategic counsel—deeply rooted in decades of first-hand experience conducting and defending these investigations—to help clients navigate these matters effectively and protect their institutional interests.
Our bipartisan team of lawyers has held senior roles on Capitol Hill and within related agencies, including the DOJ, the SEC and the offices of state attorneys general. We regularly engage with the leading investigative committees and staff in the House and Senate, giving us direct insight into committee practices, how investigations are executed and the interplay among Congress, federal agencies and other regulators. We understand the motivations behind an inquiry and how it may precede or follow other investigations, litigation or legislative developments.
We assist clients in inquiries from both chambers of Congress or multiple committees and, drawing on the resources of the Firm’s Global Government and Internal Investigations Practice, related activity by the DOJ, SEC, state attorneys general or other enforcement authorities. Our team has advised clients before committees and subcommittees responsible for oversight of energy, commerce, finance, healthcare, homeland security, technology, tax, ethics, the judiciary and national security, among others. Our deep bench and its close relationships on both sides of the aisle allow us to work effectively with committees and staff regardless of which party is in power.
Our approach is coordinated and multidisciplinary. By leveraging our cross-practice capabilities, including white collar defense, crisis management, litigation and public policy, we bring our collective legal prowess to bear for our clients—helping them navigate inquiries that can often unfold quickly, coincide with other proceedings and prompt additional regulatory scrutiny.